Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Qun‐Ying Lei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8547-8518; OpenAlex author ID A5086236254. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
12
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 10

  1. Targeting stromal metabolism in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41556-023-01330-6↗
  2. Diet high in branched-chain amino acid promotes PDAC development by USP1-mediated BCAT2 stabilization. Last author DOI 10.1093/nsr/nwab212↗
  3. [A Review of Metabolic Stress and Development of Pancreatic Cancer]. Co-author DOI 10.12182/20210160502↗
  4. Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatment. First author DOI 10.1038/s41392-020-00225-4↗
  5. Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth. Last author DOI 10.1038/s41392-020-0168-0↗
  6. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41556-019-0455-6↗
  7. Metabolism remodeling in pancreatic ductal adenocarcinoma. Last author DOI 10.15698/cst2019.12.205↗
  8. TAZ Q233del Hijacks Hippo pathway to promote mesenchymal-epithelial transition in pancreatic adenocarcinoma cells. Co-author DOI 10.1016/j.bbrc.2018.06.144↗
  9. Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer. Last author DOI 10.1016/j.molcel.2016.09.028↗
  10. Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Co-author DOI 10.1016/j.ccr.2013.02.005↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Miao Yin · 7 shared papers, 2018–2024 · strength 1.23
  2. Jintao Li · 4 shared papers, 2019–2021 · strength 0.53
  3. Mingzhu Lei · 4 shared papers, 2020–2022 · strength 0.53
  4. Yifan Zhang · 1 shared paper, 2020 · strength 0.24
  5. Jintao Li · 1 shared paper, 2022 · strength 0.14
  6. Chuan-Bo Yao · 1 shared paper, 2018 · strength 0.11
  7. Zhigang Zhang · 1 shared paper, 2020 · strength 0.09
  8. Li-Peng Hu · 1 shared paper, 2020 · strength 0.09
  9. Yingbin Liu · 1 shared paper, 2016 · strength 0.05
  10. Yi-Ping Wang · 1 shared paper, 2016 · strength 0.05
  11. Di Zhao · 1 shared paper, 2013 · strength 0.03
  12. Kun‐Liang Guan · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.